Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2022 |
Jun. 30, 2021 |
Jun. 30, 2022 |
Jun. 30, 2021 |
|
| Revenue: | ||||
| Total revenue | $ 12,703 | $ 14,471 | $ 27,446 | $ 27,652 |
| Costs and expenses: | ||||
| Cost of revenue | 14,934 | 12,460 | 30,999 | 24,185 |
| Selling, general and administrative | 20,975 | 19,079 | 43,211 | 29,199 |
| Research and development | 8,913 | 3,975 | 16,044 | 6,594 |
| Loss on sale of assets | 1 | 33 | 1 | 33 |
| Total costs and expenses | 44,823 | 35,547 | 90,255 | 60,011 |
| Loss from operations | (32,120) | (21,076) | (62,809) | (32,359) |
| Nonoperating income (expense): | ||||
| Gain (loss) on remeasurement of private warrants | 2,012 | 58,740 | 7,007 | (21,957) |
| Interest expense, net | (652) | (203) | (1,644) | (352) |
| Gain on forgiveness of debt | 1,776 | 1,776 | ||
| Loss on loan extinguishment | (2,604) | |||
| Other, net | 75 | 11 | 84 | 10 |
| Total nonoperating income (expense): | 1,435 | 60,324 | 5,447 | (23,127) |
| (Loss) income before income taxes | (30,685) | 39,248 | (57,362) | (55,486) |
| Income taxes | 240 | 531 | ||
| Net (loss) income | $ (30,445) | $ 39,248 | $ (56,831) | $ (55,486) |
| Net loss per share: | ||||
| Basic net (loss) income per share | $ (0.30) | $ 0.44 | $ (0.56) | $ (0.64) |
| Diluted net (loss) income per share | $ (0.30) | $ 0.39 | $ (0.56) | $ (0.64) |
| Weighted average number of shares used to compute | ||||
| Basic net (loss) income per share | 101,047,650 | 88,806,086 | 100,888,185 | 86,760,615 |
| Effect of dilutive instruments | 12,718,858 | |||
| Diluted net (loss) income per share | 101,047,650 | 101,524,944 | 100,888,185 | 86,760,615 |
| Products | ||||
| Revenue: | ||||
| Total revenue | $ 11,575 | $ 11,294 | $ 24,791 | $ 22,318 |
| Services | ||||
| Revenue: | ||||
| Total revenue | $ 1,128 | $ 3,177 | $ 2,655 | $ 5,334 |
| X | ||||||||||
- Definition Dilutive effect of warrants and stock options No definition available.
|
| X | ||||||||||
- Definition Gain (loss) on forgiveness of debt. No definition available.
|
| X | ||||||||||
- Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Total costs of sales and operating expenses for the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of expense (income) related to adjustment to fair value of warrant liability. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of gain (loss) on sale or disposal of assets utilized in financial service operations. No definition available.
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of the cost of borrowed funds accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|